Literature DB >> 8016789

Bronchial responsiveness and acute bronchodilator response in chronic obstructive pulmonary disease and diffuse panbronchiolitis.

H Koyama1, K Nishimura, T Mio, A Ikeda, N Sugiura, T Izumi.   

Abstract

BACKGROUND: Diffuse panbronchiolitis (DPB) is characterised clinically by chronic airflow limitation and respiratory tract infection, and pathologically by chronic bronchiolar inflammation. To elucidate the functional differences between chronic obstructive pulmonary disease (COPD) and DPB the bronchial responsiveness to methacholine was compared in 64 patients with COPD and 32 patients with DPB, and the bronchodilator response was compared in 72 patients with COPD and 49 with DPB.
METHODS: Bronchial responsiveness to methacholine was determined by the dosimeter method and expressed as PD20FEV1, and bronchodilator response was measured as the change in percentage predicted response with 5 mg nebulised salbutamol.
RESULTS: Baseline FEV1 was similar in the two groups of patients. Patients with COPD were more responsive to methacholine than were those with DPB (geometric mean PD20FEV1 8.87 v 48.0 cumulative units). Reversibility of air flow obstruction, expressed as the difference between the percentage predicted postbronchodilator FEV1 and prebronchodilator FEV1, was significantly larger in patients with COPD than in those with DPB (7.87 (6.52)% v 4.16 (4.43)%).
CONCLUSIONS: The observation that patients with DPB differ substantially in bronchial responsiveness from those with COPD is thought to reflect the difference in the mechanisms of these two diseases--that is, airway disease in DPB and more parenchymal disease in the group of patients with COPD. The nature of bronchiolar inflammation in COPD and DPB is also different, possibly explaining the difference in bronchial responsiveness. More fixed airflow limitation as a result of structural bronchiolar lesions in DPB will explain the smaller reversibility of airflow obstruction.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8016789      PMCID: PMC474939          DOI: 10.1136/thx.49.6.540

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  34 in total

Review 1.  Bronchial hyperreactivity.

Authors:  M K Benson
Journal:  Br J Dis Chest       Date:  1975-10

Review 2.  Bronchial hyperreactivity in smokers.

Authors:  N B Pride
Journal:  Eur Respir J       Date:  1988-05       Impact factor: 16.671

Review 3.  Chronic obstructive pulmonary disease: a definition and implications of structural determinants of airflow obstruction for epidemiology.

Authors:  G L Snider
Journal:  Am Rev Respir Dis       Date:  1989-09

4.  Analysis of factors associated with bronchial hyperreactivity to methacholine in bronchiectasis.

Authors:  M Ip; W K Lam; S Y So; E Liong; C Y Chan; K M Tse
Journal:  Lung       Date:  1991       Impact factor: 2.584

Review 5.  The role of allergy and nonspecific airway hyperresponsiveness in the pathogenesis of chronic obstructive pulmonary disease.

Authors:  G T O'Connor; D Sparrow; S T Weiss
Journal:  Am Rev Respir Dis       Date:  1989-07

6.  A comparison of six different ways of expressing the bronchodilating response in asthma and COPD; reproducibility and dependence of prebronchodilator FEV1.

Authors:  E Dompeling; C P van Schayck; J Molema; R Akkermans; H Folgering; P M van Grunsven; C van Weel
Journal:  Eur Respir J       Date:  1992-09       Impact factor: 16.671

7.  Bronchodilator response in chronic obstructive pulmonary disease.

Authors:  N R Anthonisen; E C Wright
Journal:  Am Rev Respir Dis       Date:  1986-05

8.  Bronchial hyperreactivity in cystic fibrosis and asthma.

Authors:  I Mitchell; M Corey; R Woenne; I R Krastins; H Levison
Journal:  J Pediatr       Date:  1978-11       Impact factor: 4.406

9.  A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis.

Authors:  J Kadota; O Sakito; S Kohno; H Sawa; H Mukae; H Oda; K Kawakami; K Fukushima; K Hiratani; K Hara
Journal:  Am Rev Respir Dis       Date:  1993-01

10.  Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis.

Authors:  H Nagai; H Shishido; R Yoneda; E Yamaguchi; A Tamura; A Kurashima
Journal:  Respiration       Date:  1991       Impact factor: 3.580

View more
  4 in total

Review 1.  Macrolides in the respiratory tract in cystic fibrosis.

Authors:  Adam Jaffé; Mark Rosenthal
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

Review 2.  Erythromycin and diffuse panbronchiolitis.

Authors:  H Koyama; D M Geddes
Journal:  Thorax       Date:  1997-10       Impact factor: 9.139

3.  Diffuse panbronchiolitis and cystic fibrosis: East meets West.

Authors:  N Høiby
Journal:  Thorax       Date:  1994-06       Impact factor: 9.139

4.  The effects of azithromycin on patients with diffuse panbronchiolitis: a retrospective study of 29 cases.

Authors:  Ding Hui; Fen Yan; Ru-Hua Chen
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.